AstraZeneca secures Fusion Pharmaceuticals in $2.4bn deal to advance cancer treatment
AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating ... Read More
AstraZeneca acquisition of Fusion Pharmaceuticals receives shareholder approval
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.'s shareholders have overwhelmingly voted in favor of the proposed acquisition by AstraZeneca. During a ... Read More
AstraZeneca to acquire Fusion Pharmaceuticals to boost cancer radioconjugate development
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of ... Read More
Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals, has announced a landmark exclusive worldwide license ... Read More